Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laszlo Radvanyi

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Science Translational Medicine|January 19, 2018
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-βYan Lan, Dong Zhang, Chunxiao Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2005
The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancerLaszlo Radvanyi, Devender Singh-Sandhu, Scott Gallichan, et al.
Neuro-Oncology|September 2, 2015
PD-L1 expression and prognostic impact in glioblastomaEdjah K Nduom, Jun Wei, Nasser K Yaghi, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
SITC strategic vision: prevention, premalignant immunity, host and environmental factorsSasha E Stanton, Kristin G Anderson, Tullia C Bruno, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 23, 2013
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccinationLuis M Vence, Chiyu Wang, Himabindu Pappu, et al.
BMJ Open|November 24, 2024
Development of the Ontario Hereditary Cancer Research Network, a unified registry as a resource for individuals with inherited cancer syndromes: an observational registry creation protocolKirsten M Farncombe, Lauren K Hughes, Elif Tuzlali, et al.
Immunity|February 10, 2021
Germline genetic contribution to the immune landscape of cancerRosalyn W Sayaman, Mohamad Saad, Vésteinn Thorsson, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Report from the Ready for the Next Round Thought-Leadership Roundtables on Building Resilience in Cancer Care and Control in Canada-Colorectal Cancer Canada; 2021Eliya Farah, Maria El Bizri, Radmila Day, et al.
The Journal of Clinical Investigation|March 26, 2024
Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesiclesPeter Ruzanov, Valentina Evdokimova, Manideep C Pachva, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Science Translational Medicine|January 19, 2018
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-βYan Lan, Dong Zhang, Chunxiao Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2005
The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancerLaszlo Radvanyi, Devender Singh-Sandhu, Scott Gallichan, et al.
Neuro-Oncology|September 2, 2015
PD-L1 expression and prognostic impact in glioblastomaEdjah K Nduom, Jun Wei, Nasser K Yaghi, et al.
Journal for Immunotherapy of Cancer|March 28, 2025
SITC strategic vision: prevention, premalignant immunity, host and environmental factorsSasha E Stanton, Kristin G Anderson, Tullia C Bruno, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 23, 2013
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccinationLuis M Vence, Chiyu Wang, Himabindu Pappu, et al.
BMJ Open|November 24, 2024
Development of the Ontario Hereditary Cancer Research Network, a unified registry as a resource for individuals with inherited cancer syndromes: an observational registry creation protocolKirsten M Farncombe, Lauren K Hughes, Elif Tuzlali, et al.
Immunity|February 10, 2021
Germline genetic contribution to the immune landscape of cancerRosalyn W Sayaman, Mohamad Saad, Vésteinn Thorsson, et al.
Current Oncology (Toronto, Ont.)|March 24, 2022
Report from the Ready for the Next Round Thought-Leadership Roundtables on Building Resilience in Cancer Care and Control in Canada-Colorectal Cancer Canada; 2021Eliya Farah, Maria El Bizri, Radmila Day, et al.
The Journal of Clinical Investigation|March 26, 2024
Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesiclesPeter Ruzanov, Valentina Evdokimova, Manideep C Pachva, et al.
Pageof 6